article thumbnail

Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)

Imaging Technology

announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4, on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status amyloid plaque in the brain.

Disease 87
article thumbnail

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

Imaging Technology

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

article thumbnail

Enigma Biomedical inks deal to develop tau PET biomarkers

AuntMinnie

Enigma Biomedical Group USA (EBG-USA) has signed an exclusive agreement to commercialize AbbVie’s tau PET imaging biomarkers for use in patients with suspected neurodegenerative disease. If the evaluations are favorable, EBG-USA has the option to negotiate an exclusive license agreement with AbbVie for the PET ligands.

article thumbnail

ImageBiopsy Lab debuts software to detect spine fractures on CT

AuntMinnie

Global pharmaceutical firm UCB developed IB Lab Flamingo's deep-learning computational model which is being integrated into the family of IB Lab Zoo orthopedic AI software modules designed to automatically analyze and extract key disease parameters that are critical for the prevention and treatment of various musculoskeletal conditions.

article thumbnail

A milestone for imaging in MASH diagnosis, treatment and monitoring

AuntMinnie

For those unfamiliar with steatotic liver disease, this is important because Rezdiffra is the first approved treatment for MASH, which if left untreated can progress to cirrhosis, require liver transplantation, and potentially cause death. Rajarshi Banerjee, MD, PhD.

Imaging 52
article thumbnail

NorthStar Medical Technologies, LLC Appoints Frank Scholz, Ph.D., as President and Chief Executive Officer

Imaging Technology

Our fast-growing portfolio encompasses promising therapeutic radioisotopes, specialty SPECT imaging agents and collaborative research for the use of therapeutic radiopharmaceuticals to treat a range of potential disease states. He has more than 30 years of experience in the biotechnology, pharmaceutical and life sciences industries.

Medical 77
article thumbnail

NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

Imaging Technology

Ac-225 with Curadh is an important step in helping to provide molecularly targeted radiation therapies for patients with cancer, and we look forward to working with them going forward.” “Molecularly targeted radiation is an exciting new field in oncology enabling us to deliver ‘systemic radiotherapy’ to patients with metastatic disease.

Medical 88